Statins for post resuscitation syndrome

Medical Hypotheses

Volumn 73, Issue 1, 2009, Pages 97-99

  Kämäräinen, Antti ^a,b   Virkkunen, Ilkka ^a,b   Silfvast, Tom ^c   Tenhunen, Jyrki ^b  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OXYGEN RADICAL; REACTIVE OXYGEN METABOLITE;

ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD CLOTTING DISORDER; BLOOD VESSEL REACTIVITY; HEART ARREST; HEART MUSCLE ISCHEMIA; HUMAN; IMMUNOMODULATION; INFLAMMATION; PLEIOTROPY; PRIORITY JOURNAL; REPERFUSION INJURY; RESUSCITATION;

ANIMALS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MODELS, IMMUNOLOGICAL; REACTIVE OXYGEN SPECIES; REPERFUSION INJURY; RESUSCITATION; SYNDROME;

EID: 64849106456     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2009.01.021     Document Type: Article

References (36)

1. Nolan J.P., and Soar J. Post resuscitation care - time for a care bundle?. Resuscitation 76 (2008) 161-162
2. Adrie C., Adib-Conquy M., Laurent I., et al. Successful cardiopulmonary resuscitation after cardiac arrest as a "sepsis-like" syndrome. Circulation 106 (2002) 562-568
3. Adrie C., Monchi M., Laurent I., et al. Coagulopathy after successful cardiopulmonary resuscitation following cardiac arrest: implication of the protein C anticoagulant pathway. J Am Coll Cardiol 46 (2005) 21-28
4. Hekimian G., Baugnon T., Thuong M., et al. Cortisol levels and adrenal reserve after successful cardiac arrest resuscitation. Shock 22 (2004) 116-119
5. Ames A.I., Wright R., Kowada M., Thurston J.M., and Majno G. Cerebral ischemia II. The no-reflow phenomenon. Am J Pathol 52 (1968) 437-453
6. Chiang J., Kowada M., Ames III A., Wright R.L., and Majno G. Cerebral ischemia III. Vascular changes. Am J Pathol 52 (1968) 455-476
7. Popp E., and Bottiger B.W. Cerebral resuscitation: state of the art, experimental approaches and clinical perspectives. Neurol Clin 24 (2006) 73-87
8. Safar P., Behringer W., Bottiger B., and Sterz F. Cerebral resuscitation potentials for cardiac arrest. Crit Care Med 30 (2002) S140-S4
9. Buunk G., van der Hoeven J.G., and Meinders A.E. Cerebrovascular reactivity in comatose patients resuscitated from a cardiac arrest. Stroke 28 (1997) 1569-1573
10. Buunk G., van der Hoeven J.G., Meinders A.E., and Frölich M. Cerebral vasoconstriction in comatose patients resuscitated from a cardiac arrest?. Intensive Care Med 22 (1996) 1191-1196
11. Greer D.M.D. Mechanisms of injury in hypoxic-ischemic encephalopathy: implications to therapy. Semin Neurol 26 (2006) 373-379
12. Rincon F., and Mayer S. Therapeutic hypothermia for brain injury after cardiac arrest. Semin Neurol 26 (2006) 387-395
13. Laver S., Farrow C., Turner D., and Nolan J. Mode of death after admission to an intensive care unit following cardiac arrest. Intensive Care Med 30 (2004) 2126-2128
14. Vaughan C.J., Murphy M.B., and Buckley B.M. Statins do more than just lower cholesterol. Lancet 348 (1996) 1079-1082
15. Takemoto M., and Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 21 (2001) 1712-1719
16. Böttinger B.W., Motsch J., Böhrer H., et al. Activation of blood coagulation after cardiac arrest is not balanced adequately by activation of endogenous fibrinolysis. Circulation 92 (1995) 2572-2578
17. Gando S., Kameue T., Nanzaki S., et al. Platelet activation with massive formation of thromboxane A2 during and after cardiopulmonary resuscitation. Intensive Care Med 23 (1997) 71-76
18. Gando S., Kameue T., Nanzaki S., et al. Massive fibrin formation with consecutive impairment of fibrinolysis in patients with out-of-hospital cardiac arrest. Thromb Haemost 77 (1997) 278-282
19. + and membrane dynamics in patients with primary hypercholesterolemia: effects of pravastatin. Arterioscler Thromb Vasc Biol 15 (1995) 759-764
20. Huhle G., Abletshauser C., Mayer N., Weidinger G., Harenberg J., and Heene D.L. Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA-reductase inhibitor. Thromb Res 95 (1999) 229-234
21. Vaughan C.J., Gotto Jr. A.M., and Basson C.T. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 35 (2000) 1-10
22. Lijnen P., Echevaria-Vazquez D., and Petrov V. Influence of cholesterol lowering on plasma membrane lipids and function. Meth Find Exp Clin Pharmacol 18 (1996) 123-136
23. Essig M., Nguyen G., Prie D., Escoubet B., Sraer J.D., and Friedlander G. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells: role of geranylgeranylation and Rho proteins. Circ Res 83 (1998) 683-690
24. Gando S., Nanzaki S., Morimoto Y., Kobayashi S., and Kemmotsu O. Tissue factor and tissue factor pathway inhibitor levels during and after cardiopulmonary resuscitation. Thromb Res 96 (1999) 107-113
25. Pahan K., Sheikh F.G., Namboodiri A.M., and Singh I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest 100 (1997) 2671-2679
26. Aikawa M., Rabkin E., Sugiyama S., et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases, and tissue factor in vivo, and in vitro. Circulation 103 (2001) 276-283
27. Inoue I., Goto S., Mizotani K., et al. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells. Life Sci 67 (2000) 863-876
28. Kothe H., Dalhoff K., Rupp J., et al. Hydroxymethylglutaryl coenzyme: a reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae. Circulation 101 (2000) 1760-1763
29. Bustos C., Hernandez-Presa M.A., Ortego M., et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 32 (1998) 2057-2064
30. Scalia R., Gooszen M.E., Jones S.P., et al. Simvastatin exerts both anti-inflammatory and cardioprotective effects in apolipoprotein e-deficient mice. Circulation 103 (2001) 2598-2603
31. Hernandez-Perera O., Perez-Sala D., Navarro-Antolin J., et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 101 (1998) 2711-2719
32. Laufs U., La Fata V., Plutzky J., and Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97 (1998) 1129-1135
33. Harrison D.G. Endothelial function and oxidant stress. Clin Cardiol 20 Suppl. II (1997) II-11-II-17
34. Munzel T., Sayegh H., Freeman B.A., Tarpey M.M., and Harrison D.G. Evidence for enhanced vascular superoxide anion production in nitrate tolerance: a novel mechanism underlying tolerance and cross-tolerance. J Clin Invest 95 (1995) 187-194
35. Rikitake Y., Kawashima S., Takeshita S., et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 154 (2001) 87-96
36. Wassmann S., Laufs U., Baumer A.T., et al. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol 59 (2001) 646-654